Evidence and Current Use of Levosimendan in the Treatment of Heart Failure: Filling the Gap

Autor: Conti N, Gatti M, Raschi E, Diemberger I, Potena L

Publikováno v: Drug Design, Development and Therapy, Vol Volume 15, Pp 3391-3409 (2021)

Nicolina Conti,1 Milo Gatti,2,3 Emanuel Raschi,2 Igor Diemberger,1,4 Luciano Potena4 1Cardiology Unit, Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum - University of Bologna, Bologna, Italy; 2Pharmacology Unit, De

Externí odkaz: https://doaj.org/article/91a7cdd5935d4636b2fb73160ed6d946

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Safety of COVID-19 Vaccines Among the Paediatric Population: Analysis of the European Surveillance Systems and Pivotal Clinical Trials

Autor: Ahmadizar F., Luxi N., Raethke M., Schmikli S., Riefolo F., Saraswati P. W., Bucsa C., Osman A., Liddiard M., Maques F. B., Petrelli G., Sonderlichova S., Thurin N. H., Villalobos F., Trifiro G., Sturkenboom M., Moretti U., Bellitto C., Ciccimarra F., Gonella L. A., Arzenton E., Chiamulera C., Lora R., Bellantuono D., Sabaini A., Firenze A., Zodda D., Guidotti F., Zappone M., Alagna B., Cutroneo P. M., Minore C., Costantino C., Vitale F., D'Alessandro G., Morreale I., Marsala L., Farinella D., Bavetta S., Fantini M. P., Reno C., Raschi E., Poluzzi E., Sapigni E., Potenza A. M., Podetti D., Nikitina V., Ricciardelli R., Mogheiseh N., Croce S., Paltrinieri B., Castellani S., Sangiorgi E., Selleri M., Lucchesi S., Catucci G., Savini D., Sacripanti C., Faccioli M., Romio M. S., Rossi L., Radici S., Negri G., Fares L., Ajolfi C., Fadda A., Chiarello A., Pieraccini F., Gavioli B., Palazzi S., Tuccori M., Vannacci A., Bonaiuti R., Ravaldi C., Lombardi N., Crescioli G., Gori F., Tessari R., Zandona E., Zanoni G., Senna G., Crivellaro M. A., Cancian M., Venturini F., Ferri M., Leonardi L., Orzetti S., Caccin E., Baldo P., Capuano A., Rafaniello C., Ferrajolo C., Pagliaro C., Mercaldo M., di Giorgio A., Tari M., Manna S., Farina G., Di Mauro C., De Carlo I., Senesi I., Pileggi C., Palleria C., Gallelli L., De Sarro G., de Sarro C., Verduci C., Papadopoli R., Trabace L., Morgese M., Schiavone S., Tucci P., Bove M., Lapi F., Cricelli C., Racagni G., Tonolo S., Fava G., Giuffrida S., Amato V., Gambera M., Montresor V., Mastropasqua D.

Background and Objectives: The European Medicine Agency extended the use of Comirnaty, Spikevax, and Nuvaxovid in paediatrics; thus, these vaccines require additional real-world safety evidence. Herein, we aimed to monitor the safety of COVID-19 vacc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______4094::c8916ae0b4845b6e45ea4bd7d0d193b1
https://hdl.handle.net/11585/928075

Identifying Medications Underlying Communication Atypicalities:A Pharmacosurveillance Study Within the FDA Adverse Event Reporting System

Autor: Fusaroli, Michele, Simonsen, Arndis, Borrie, Stephanie, Low, Daniel, Parola, Alberto, Raschi, E., Poluzzi, E., Fusaroli, Riccardo

Publikováno v: Fusaroli, M, Simonsen, A, Borrie, S, Low, D, Parola, A, Raschi, E, Poluzzi, E & Fusaroli, R 2022, ' Identifying Medications Underlying Communication Atypicalities : A Pharmacosurveillance Study Within the FDA Adverse Event Reporting System ', Drug Safety, vol. 45, no. 10, pp. 1134-1134 . https://doi.org/10.1101/2022.09.05.22279609

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pure_au_____::963d580e3fef1a36b18761c7b36f8b3f
https://pure.au.dk/portal/da/publications/identifying-medications-underlying-communication-atypicalities(82571614-fa66-4d4a-85d3-821c64c0b028).html

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.